https://www.selleckchem.com/pr....oducts/ac-fltd-cmk.h
In non-alcoholic fatty liver disease (NAFLD), fibrosis determines the risk of liver complications. Non-invasive tests (NITs) such as FIB-4, NAFLD Fibrosis Score (NFS) and Hepamet, have been proposed as a tool to triage NAFLD patients in primary care (PC). These NITs include AST±ALT in their calculations. Many patients with NAFLD take statins, which can affect AST/ALT, but it is unknown if statin affects NITs fibrosis prediction. We included 856 patients referred through a standardised pathway from PC with a final diagnosis of NAFLD.
Мне нравится
Комментарий
Перепост
